![](/images/graphics-bg.png)
Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine
Joint Authors
Samarah, Fekri
Dumaidi, Kamal
Al-Jawabreh, Amer
Rabayaa, Maha
Source
Canadian Journal of Infectious Diseases and Medical Microbiology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-05
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background.
HCV and HBV present a great challenge in the management of β-thalassemia patients.
Objective.
The present study aimed to determine the prevalence of both HBV and HCV in multitransfused-dependent β-thalassemia patients in northern West Bank, Palestine, using sero-molecular markers.
Methods.
Serum sample from 139 multitransfused β-thalassemia patients were tested for HBV and HCV markers including HBsAg, anti-HBc, anti-HBs, HBV-DNA, and anti-HCV and HCV-RNA.
Demographic data and selected clinical parameters were collected by means of a questionnaire and from the patients’ medical files.
Results and Conclusion.
The mean (±SD) age of patients was 18.1 years (±10.6).
The overall prevalence of the HCV was 10% (14/139), which is 50 times higher than the normal Palestinian population (0.2%).
Of which, 3 were positive for anti-HCV alone, 7 positives for HCV-RNA alone, and 4 positives for both anti-HCV and PCR-RNA.
On the other hand, low prevalence of HBV was detected at a level of 0.7% (1/139).
Only one patient had HCV-HBV coinfection.
Twenty-five patients (19%) were positive for anti-HBc, while 99 (71%) were immune with the anti-HBs level above 10 IU/mL.
Anti-HBc was insignificantly high (P=0.07) in HCV-positive cases.
In conclusion, the prevalence of HCV among β-thalassemia patients is considered high compared to normal population.
Determination of HCV prevalence should be based on the detection of both HCV-RNA and anti-HCV.
On the contrary, HBV showed a low prevalence.
A follow-up schedule and administration of booster dose of HBV vaccine is strongly recommended for β-thalassemia patients whose anti-HBs level <10 IU/ml.
American Psychological Association (APA)
Dumaidi, Kamal& Al-Jawabreh, Amer& Samarah, Fekri& Rabayaa, Maha. 2018. Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1131113
Modern Language Association (MLA)
Dumaidi, Kamal…[et al.]. Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1131113
American Medical Association (AMA)
Dumaidi, Kamal& Al-Jawabreh, Amer& Samarah, Fekri& Rabayaa, Maha. Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine. Canadian Journal of Infectious Diseases and Medical Microbiology. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1131113
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1131113